AURO-CEFEPIME 2 g; cefepime (as hydrochloride) 2 g powder for injection vial

Երկիր: Ավստրալիա

Լեզու: անգլերեն

Աղբյուրը: Department of Health (Therapeutic Goods Administration)

Ակտիվ բաղադրիչ:

cefepime, Quantity: 2000 mg

Հասանելի է:

Strides Pharma Science Pty Ltd

INN (Միջազգային անվանումը):

Cefepime

Դեղագործական ձեւ:

Injection, powder for

Կազմը:

Excipient Ingredients: arginine

Կառավարման երթուղին:

Intravenous, Intramuscular

Միավորները փաթեթում:

5 vials, 1 vial

Ռեկվիզորի տեսակը:

(S4) Prescription Only Medicine

Թերապեւտիկ ցուցումներ:

Adults: Cefepime is indicated in the treatment of the infections listed below when caused by susceptible bacteria.. - Lower respiratory tract infections, including pneumonia and bronchitis. - Urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. - Skin and skin structure infections. Intra-abdominal infections, including peritonitis and biliary tract infections. - Gynaecological infections. Septicaemia. - Empirical treatment in febrile neutropenic patients (see Precautions). Cefepime is also indicated for surgical prophylaxis in patients undergoing intra-abdominal surgery. In this indication it is essential that metronidazole also be administered. Paediatrics: Cefepime is indicated in paediatric patients over 2 months of age for the treatment of the infections listed below when caused by susceptible bacteria. Pneumonia. - Urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. - Skin and skin structure infections. - Septicaemia. - Empirical treatment in febrile neutropenic patients (see Precautions). Culture and susceptibility studies should be performed when appropriate to determine susceptibility of the causative organism(s) to cefepime. Empirical therapy with Cefepime may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. Because of its broad spectrum of bactericidal activity against Gram positive and Gram negative bacteria, Cefepime can be used appropriately as monotherapy prior to identification of the causative organisms(s). In the treatment of febrile neutropenia, consideration should be given to the need for other antibiotics in combination with Cefepime. In patients who are at risk of mixed aerobic/ anaerobic infection, including infections in which Bacterioides fragilis may be present, concurrent initial therapy with an antianaerobic agent is recommended before the causative organism(s) is known.

Ապրանքի ամփոփագիր:

Visual Identification: White to pale yellow powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Լիազորման կարգավիճակը:

Licence status A

Հաստատման ամսաթիվը:

2010-08-26